Understanding OUR Cytokine-Based Immunotherapy Candidates Our commitment extends to advancing a robust portfolio of programs directed at expanding the horizons of cytokine-based immunotherapy, specifically for cancers where treatment method choices remain limited. Use the links below to learn extra about our portfolio of cytokine-based immunotherapy candidates. Examine Our Pipeline https://financefeeds.com/swissquote-sets-ambitious-2028-pre-tax-profit-target-chf-500-million/